Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker

Biochemical and Biophysical Research Communications

Volumn 306, Issue 1, 2003, Pages 16-25

  Nakatsura, Tetsuya ^a   Yoshitake, Yoshihiro ^a   Senju, Satoru ^a   Monji, Mikio ^a   Komori, Hiroyuki ^a   Motomura, Yutaka ^a   Hosaka, Seiji ^a   Beppu, Toru ^b   Ishiko, Takatoshi ^b   Kamohara, Hidenobu ^b   Ashihara, Hiroshi ^b   Katagiri, Toyomasa ^c   Furukawa, Yoichi ^c   Fujiyama, Shigetoshi ^b   Ogawa, Michio ^b   Nakamura, Yusuke ^c   Nishimura, Yasuharu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

cDNA microarray; Glypican 3; Hepatocellular carcinoma; Oncofetal protein; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; COMPLEMENTARY DNA; DECARBOXYPROTHROMBIN; GLYPICAN 3; MEMBRANE PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CHRONIC HEPATITIS; CONTROLLED STUDY; DNA MICROARRAY; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFORMED CONSENT; JAPAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0038054270     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00908-2     Document Type: Article

References (26)

1. Schafer D.F., Sorrell M.F. Hepatocellular carcinoma. Lancet. 353:1999;1253-1257.
2. Okuda K. Hepatocellular carcinoma. J. Hepatol. 32:2000;225-237.
3. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 286:1999;531-537.
4. Okabe H., Satoh S., Kato T., Kitahara O., Yanagawa R., Yamaoka Y., Tsunoda T., Furukawa Y., Nakamura Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 61:2001;2129-2137.
5. Saito-Hisaminato A., Katagiri T., Kakiuchi S., Nakamura T., Tsunoda T., Nakamura Y. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res. 9:2002;35-45.
6. Nakatsura T., Senju S., Yamada K., Jotsuka T., Ogawa M., Nishimura Y. Gene cloning of immunogenic antigens over-expressed in pancreatic cancer. Biochem. Biophys. Res. Commun. 281:2001;936-944.
7. Zhu Z.W., Friess H., Wang L., Abou-Shady M., Zimmermann A., Lander A.D., Korc M., Kleeff J., Buchler M.W. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 48:2001;558-564.
8. Hsu H.C., Cheng W., Lai P.L. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 57:1997;5179-5184.
9. Pilia G., Hughes-Benzie R.M., MacKenzie A., Baybayan P., Chen E.Y., Huber R., Neri G., Cao A., Forabosco A., Schlessinger D. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat. Genet. 12:1996;241-247.
10. Neri G., Gurrieri F., Zanni G., Lin A. Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am. J. Med. Genet. 79:1998;279-283.
11. Behmel A., Plochl E., Rosenkranz W.A. A new X-linked dysplasia gigantism syndrome: identical with the Simpson dysplasia syndrome? Hum. Genet. 67:1984;409-413.
12. Garganta C.L., Bodurtha J.N. Report of another family with Simpson-Golabi-Behmel syndrome and a review of the literature. Am. J. Med. Genet. 44:1992;129-135.
13. Golabi M., Rosen L. A new X-linked mental retardation overgrowth syndrome. Am. J. Med. Genet. 17:1984;345-358.
14. Gurrieri F., Cappa M., Neri G. Further delineation of the Simpson-Golabi-Behmel (SGB) syndrome. Am. J. Med. Genet. 44:1992;136-137.
15. Hughes-Benzie R.M., Pilia G., Xuan J.Y., Hunter A.G., Chen E., Golabi M., Hurst J.A., Kobori J., Marymee K., Pagon R.A., Punnett H.H., Schelley S., Tolmie J.L., Wohlferd M.M., Grossman T., Schlessinger D., MacKenzie A.E. Simpson-Golabi-Behmel Syndrome: genotype/phenotype analysis of 18 affected males from 7 unrelated families. Am. J. Med. Genet. 66:1996;227-234.
16. Xuan J.Y., Hughes-Benzie R.M., Mackenzie A.E. A small interstitial deletion in the GPC3 gene causes Simpson-Golabi-Behmel syndrome in a Dutch-Canadian family. J. Med. Genet. 36:1999;57-58.
17. Cano-Gauci D.F., Song H.H., Yang H., McKerlie C., Choo B., Shi W., Pullano R., Piscione T.D., Grisaru S., Soon S., Sedlackova L., Tanswell A.K., Mak T.W., Yeger H., Lockwood G.A., Rosenblum N.D., Filmus J. Glypican-3-deficient mice exhibit the overgrowth and renal abnormalities typical of the Simpson-Golabi-Behmel syndrome. J. Cell Biol. 146:1999;255-264.
18. Duenas G.A., Kaya M., Shi W., Song H., Testa J.R., Penn L.Z., Filmus J. OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J. Cell Biol. 141:1998;1407-1414.
19. Lin H., Huber R., Schlessinger D., Morin P.J. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res. 59:1999;807-810.
20. Murthy S.S., Shen T., De Rienzo A., Lee W.C., Ferriola P.C., Jhanwar S.C., Mossman B.T., Filmus J., Testa J.R. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene. 19:2000;410-416.
21. Xiang Y.Y., Ladeda V., Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene. 20:2001;7408-7412.
22. Yayon A., Klagsbrun M., Esko J.D., Leder P., Ornitz D.M. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 64:1991;841-848.
23. Schlessinger J., Lax I., Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell. 83:1995;357-360.
24. Coggin J.H. Jr. The implications of embryonic gene expression in neoplasia. CRC Cr. Rev. Oncol.-Hematol. 5:1992;37-55.
25. Matsuura H., Hakomori S.I. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc. Natl. Acad. Sci. USA. 82:1985;6517-6521.
26. Fujiyama S., Tanaka M., Maeda S., Ashihara H., Hirata R., Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology. 62:2002;57-63.